TEC-001 with transarterial embolization (TATE) uses a well-established procedure to shut off blood supply to the tumor to create the hypoxic environment necessary for drug activation. TATE has the potential to enhance the efficacy of FDA-approved immune checkpoint inhibitors (ICIs) and transform the standard of care for patients battling cancer. TEC-001 works with ICIs to generate a systemic anticancer immune response that can target cancer cells throughout the body. This durable anticancer immunity helps safeguard against future cancer growth and promote lasting remission.
Our next candidate, TEC-002 converts solid tumors into the ideal environment for TEC-001 activation. TEC-002 and TEC-001 have the potential to systemically treat nearly all solid tumor indications by eliminating the need for TATE.
Our approaches promise novel treatments for solid tumors, extending lives and challenge current treatment paradigm for patients who have exhausted treatment options.
Teclison has completed the End of Phase 2 Meeting with the FDA, and we are ready for a phase 3 registrational study for metastatic CRC. Phase 2 trials are ongoing for our lung, liver, gastric, and neuroendocrine TATE cancer programs.
Teclison is actively expanding treatment indications so more cancer types can be treated with this highly specific, tumor-targeting strategy, bringing new hope for patients who have developed resistance to standard of care.
Targeted future indications